WO2011058764A1 - Préparation pour gargarisme, procédé et appareil pour sa production - Google Patents

Préparation pour gargarisme, procédé et appareil pour sa production Download PDF

Info

Publication number
WO2011058764A1
WO2011058764A1 PCT/JP2010/006682 JP2010006682W WO2011058764A1 WO 2011058764 A1 WO2011058764 A1 WO 2011058764A1 JP 2010006682 W JP2010006682 W JP 2010006682W WO 2011058764 A1 WO2011058764 A1 WO 2011058764A1
Authority
WO
WIPO (PCT)
Prior art keywords
gargle
water
ppm
carbon dioxide
stock solution
Prior art date
Application number
PCT/JP2010/006682
Other languages
English (en)
Japanese (ja)
Inventor
宗則 野口
Original Assignee
パーフェクトペリオ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パーフェクトペリオ株式会社 filed Critical パーフェクトペリオ株式会社
Publication of WO2011058764A1 publication Critical patent/WO2011058764A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to a gargle, a method for producing the same, and a device for producing the same, mainly for the sterilization of viruses that cause infections in human bodies due to respiratory tract infection.
  • Infectious diseases caused by viruses begin with the adsorption of viruses to human cells, which part of the body becomes the site of entry of the virus varies from virus to virus. , Contact infection and wound infection.
  • viruses that have caused respiratory tract infection as an entry gate include influenza virus, coronavirus, which is a pathogen of SARS, measles virus, rubella virus, and the like.
  • Poppylon iodine is widely known as a mouthwash that can remove viruses, that is, an gargle, and iodine in the ingredients often shows a certain effectiveness against pathogenic microorganisms such as viruses and fungi and bacteria.
  • Patent Document 1 Known (Patent Document 1).
  • Non-Patent Document 1 New influenza (A / H1N1), which is showing a worldwide epidemic at the time of filing, has a larger scale of infection than seasonal influenza, and therefore, safer and more reliable infection prevention measures have become more urgent than before.
  • the present invention has been made in consideration of the above-described circumstances, and provides a gargle capable of removing viruses in the vicinity of the pharynx without damaging epithelial cells of the pharynx, a method for producing the same, and a device for producing the same. With the goal.
  • the gargle according to the present invention has an effective chlorine concentration of 50 to 300 ppm, a pH of 6.3 to 8, contains hypochlorous acid and sodium bicarbonate, and is present in the pharynx. It is intended for virus removal.
  • the gargle according to the present invention has an effective chlorine concentration of 50 to 250 ppm.
  • the gargle according to the present invention has the effective chlorine concentration of 50 to 200 ppm.
  • the gargle according to the present invention has a pH of 7-8 instead of 6.3-8.
  • the method for producing a gargle according to the present invention is used for removing viruses present in the pharynx, and an aqueous solution to which sodium chloride and carbon dioxide are added is used as a stock solution.
  • a method for producing a gargle that produces hypochlorous acid and sodium hydrogen carbonate having a predetermined concentration by electrolyzing so as to have an effective chlorine concentration of 50 to 300 ppm and a pH of 6.3 to 8.
  • the stock solution By passing water through a reverse osmosis membrane, adding sodium chloride to the passing water, blowing carbon dioxide or adding dry ice simultaneously with or before and after the sodium chloride addition step, By adding sodium chloride to pure water or distilled water, blowing carbon dioxide or adding dry ice simultaneously with or before and after the sodium chloride addition step, By passing water through a reverse osmosis membrane, adding sodium chloride to the passing water, and making the partial pressure of carbon dioxide in contact with the passing water higher than the partial pressure in the atmosphere, or While adding sodium chloride to pure water or distilled water, by making the carbon dioxide partial pressure in contact with the pure water or the distilled water higher than the partial pressure in the atmosphere, Each is made.
  • the method for producing a gargle according to the present invention is such that the effective chlorine concentration is 50 to 250 ppm.
  • the method for producing a gargle according to the present invention is such that the effective chlorine concentration is 50 to 200 ppm.
  • the method for producing a gargle according to the present invention is such that the pH is 7 to 8 instead of 6.3 to 8.
  • the gargle production apparatus is an apparatus for producing a gargle for the purpose of removing viruses present in the pharynx as described in claim 9, to which sodium chloride and carbon dioxide are added.
  • the electrolytic bath has an effective chlorine concentration of 50 to 300 ppm by electrolyzing the stock solution,
  • the pH is 6.3 to 8, and a gargle containing hypochlorous acid and sodium hydrogen carbonate is produced.
  • the gargle producing apparatus has an effective chlorine concentration of 50 to 250 ppm.
  • the gargle producing apparatus has the effective chlorine concentration of 50 to 200 ppm.
  • the gargle producing apparatus according to the present invention has a pH of 7 to 8 instead of 6.3 to 8.
  • Viruses die outside of living cells in a very short time unless they are in a special environment, but once they have entered the living cells, they escape from humoral immunity and proliferate parasitically in the cells.
  • Mouthwashes based on cineol and thymol and gargles based on poppyon iodine have been verified to have certain bactericidal properties against such viruses, but on the other hand, There is also concern about the toxicity to epithelial cells.
  • the gargle according to the present invention has sodium bicarbonate (NaHCO 3 ) functioning as a buffer, and the pH of the entire gargle is maintained in the range of 6.3 to 8, thus ensuring safety for the human body.
  • NaHCO 3 sodium bicarbonate
  • the virus present in the pharynx can be killed by the bactericidal power of hypochlorous acid (HClO) present at a high level.
  • the effective chlorine concentration is 50 ppm or more and the abundance ratio of hypochlorous acid (HClO) is set to a pH range, it enters the epithelial cells of the pharynx and exists in the cytoplasm The virus can be reliably killed with hypochlorous acid.
  • the effective chlorine concentration is set to 300 ppm or less, preferably 250 ppm or less, more preferably 200 ppm or less. It is possible to minimize the damage to the cells and to surely avoid the death of the epithelial cells.
  • the above-mentioned hypochlorous acid shows high bactericidal activity against bacteria composed of prokaryotic cells not having a nuclear membrane, and can surely kill bacteria living in the pharynx.
  • hypochlorous acid selectively kills only viruses that invade the cytoplasm that makes up the pharyngeal epithelial cells and bacteria that inhabit the pharynx, while minimizing damage to the pharyngeal epithelial cells. It becomes possible.
  • Hypochlorous acid has a property of easily binding to an amino group, but since the virus is covered with a protein called capsid, the virus can be easily destroyed.
  • sodium hydrogencarbonate (NaHCO 3 ) is a hypochlorous acid to virus by destroying the biofilm in a situation where the biofilm inhibits hypochlorous acid (HClO) from contacting the virus. It also serves to allow acid (HClO) contact.
  • the target virus in the present invention is an invasion site serving as an entrance of infection to the human body, that is, the intrusion gate is the upper respiratory tract (range from the oral cavity and nasal cavity to the larynx through the pharynx), specifically, Influenza virus, measles virus, rubella virus, varicella virus, mumps virus which is a pathogen of epidemic parotitis, and coronavirus which is a pathogen of SARS.
  • the intrusion gate is the upper respiratory tract (range from the oral cavity and nasal cavity to the larynx through the pharynx), specifically, Influenza virus, measles virus, rubella virus, varicella virus, mumps virus which is a pathogen of epidemic parotitis, and coronavirus which is a pathogen of SARS.
  • forced dissolution of carbon dioxide means that the solubility of carbon dioxide is higher than the concentration at which it can be dissolved naturally (the solubility under the partial pressure of carbon dioxide present in the atmosphere).
  • the stock solution may be prepared by any of the following methods (a) to (d). In any of these methods, hydrochloric acid, acetic acid or other carbonic acid is used. Do not add any acid except. Therefore, the main solution composition condition is the amount of sodium chloride added.
  • the water that is a component of the stock solution in (a) and (c) can use well water, tap water, etc., and it is not necessary to use pure water.
  • the reason why the pH is desirably 7 or more is that it is possible to prevent acidification in the oral cavity caused by lactic acid produced by cariogenic pathogenic bacteria.
  • the effective chlorine concentration is 50 to 300 ppm is that if it is less than 50 ppm, it is difficult to kill the virus because of its low bactericidal activity. If it exceeds 300 pm, the cell nucleus is surrounded by the nuclear membrane. Nonetheless, there are concerns about injury to epithelial cells in the human body.
  • the reason why the effective chlorine concentration is desirably 50 to 250 ppm is that the concern about the damage to the epithelial cells can be further reduced, and more desirably 50 to 200 ppm is the possibility of the damage to the epithelial cells. This is because it can be made substantially zero.
  • the gargle according to this embodiment contains hypochlorous acid (HClO) and sodium hydrogen carbonate (NaHCO 3 ), and the effective chlorine concentration is 50 to 300 ppm, preferably 50 to 250 ppm, more preferably 50 to 200 ppm.
  • the pH is 6.3 or more and 8 or less, preferably 7 or more and 8 or less, and the purpose is to remove viruses present in the pharynx.
  • FIG. 1 shows an apparatus for producing a gargle according to this embodiment.
  • the gargle generating apparatus 51 includes a stock solution tank 3 that stores a stock solution 52, a stroke pump 4 that is connected to the stock solution tank, and a communication pump that is connected to the stroke pump.
  • the installation position of the dilution water tank 8 is relatively positioned with respect to the tip position of the discharge pipe 6 so as to be equal to or lower than the water level of the water 57.
  • the stock solution 52 is prepared by any of the methods described below, but no acid other than hydrochloric acid, acetic acid or other carbonic acid is added in any of the methods.
  • the dilution water 57 may be well water, tap water, pure water or any other water, but the pH is appropriately selected so that the pH of the gargle to be generated is in the above-mentioned range.
  • the generation apparatus 51 further includes a deaeration module 11 in which the water injection side is communicated with the secondary generation water 60 obtained by diluting the primary generation water with the dilution water 57 in the dilution water tank 8.
  • the deaeration module is adapted to remove dissolved oxygen from the secondary product water 60 by decompression by the vacuum pump 12, and contains the tertiary product water from which the dissolved oxygen has been removed from the secondary product water 60.
  • the tubes used in the generation device 51 or the electromagnetic valve provided as necessary may be deteriorated by oxidation with a high concentration of hypochlorous acid, so that it is desirable to form with fluorine.
  • the effective chlorine concentration of the tertiary product water is 50 to 300 ppm, desirably 50 to 250 ppm, more desirably 50 to 200 ppm.
  • the composition conditions of the stock solution 52 mainly the amount of sodium chloride added
  • the operating conditions during the electrolysis eg voltage value and current value
  • dilution so that the pH is 6.3 to 8, preferably 7 to 8.
  • the conditions are determined, and the blended stock solution 52 is stored in the stock solution tank 3.
  • Sodium chloride is added, for example, 2 to 5% by mass.
  • the method for temporarily increasing the solubility of carbon dioxide can be further classified into either a method by blowing carbon dioxide or a method by adding dry ice.
  • temporary means that the partial pressure of carbon dioxide in contact with the solvent is equal to the partial pressure of carbon dioxide present in the atmosphere.
  • carbon dioxide is mixed at atmospheric pressure, Even when forced press-fitting is performed, the solubility of carbon dioxide decreases with time due to pressure equilibrium with the partial pressure of carbon dioxide contained in the air. In this case, it is necessary to perform electrolytic treatment promptly before the solubility of carbon dioxide decreases.
  • the water is passed through a reverse osmosis membrane, pure water or distilled water is used as a solvent, and the solvent is sealed in an airtight tank.
  • a method in which carbon dioxide is injected or carbon dioxide gas is blown into a solvent in an airtight tank or dry ice is added to the solvent can be employed.
  • the forced dissolution of carbon dioxide is made by selecting one of the following methods.
  • the water that passes through the reverse osmosis membrane may be of any property, but it is purified to some extent in the sense of reducing the burden on the reverse osmosis membrane and the water purifier using it, or reducing the amount of waste water as much as possible.
  • Water is desirable.
  • ground water, tap water, or commercially available mineral water (commercial water) can be used.
  • tap water is used as the water that passes through the reverse osmosis membrane.
  • the stock solution 52 is then weighed in an amount corresponding to one batch of gargle and stored in the stock solution tank 3, and diluted water 57 of an amount corresponding to one batch of gargle is also added.
  • the dilution water tank 8 Stored in the dilution water tank 8.
  • the amount of the dilution water 57 corresponding to one batch of the gargle may be appropriately determined according to the dilution rate and the pH of the dilution water.
  • the stock solution 52 is sent to the electrolytic cell 5 by the stroke pump 4, and the electrolytic cell 5 is operated under predetermined operating conditions to electrolyze the stock solution 52.
  • the primary generated water generated in the electrolytic cell 5 is injected into the diluted water 57 previously stored in the diluted water tank 8 through the discharge pipe 6 connected to the electrolytic cell.
  • the installation position of the dilution water tank 8 is relatively positioned so that the tip position of the discharge pipe 6 is equal to or lower than the water level of the dilution water 57 stored in the dilution water tank 8.
  • the primary product water is injected into the dilution water 57 through the discharge pipe 6 without coming into contact with air (outside air).
  • the primary product water is injected into the diluting water 57 weighed in advance in a so-called batch system, the primary product water is diluted with the dilution water unlike conventional mixing in the pipe. 57 is mixed homogeneously.
  • the secondary generated water 60 is passed through the degassing module 11 to generate tertiary generated water from which dissolved gas, particularly dissolved oxygen is removed, and this is stored in the tertiary generated water tank 14 as a gargle 33. To do.
  • the gargle may be contained in the oral cavity for several seconds to several tens of seconds.
  • the pH of the entire gargle is maintained in the range of 6.3 to 8 in which the abundance ratio of hypochlorous acid (HClO) is kept high by sodium hydrogen carbonate (NaHCO 3 ), and is contained in the gargle 63. While the virus present in the pharynx is rapidly removed by the bactericidal power of hypochlorous acid (HClO), the safety to the human body is ensured by the buffer action by sodium hydrogen carbonate (NaHCO 3 ).
  • an aqueous solution to which sodium chloride and carbon dioxide are added is used as a stock solution, and the stock solution has an effective chlorine concentration of 50 to 50. 300 ppm, preferably 50-250 ppm, more preferably 50-200 ppm, and the pH is 6.3-8, preferably 7-8. Electrolysis is performed so that the virus present in the pharynx can be sterilized. It becomes possible to produce hypochlorous acid having a concentration and sodium hydrogen carbonate (NaHCO 3 ) capable of maintaining a pH environment where the abundance ratio of hypochlorous acid is high.
  • NaHCO 3 sodium hydrogen carbonate
  • the production method and the production apparatus 51 of the gargle 63 since carbon dioxide is forcibly dissolved, a high concentration sodium hydrogen carbonate is produced and resistance to pH fluctuation ( It is possible to produce a tasteless and odorless gargle because there is no need to add acid such as hydrochloric acid or acetic acid, and even if the effective chlorine concentration is 300 ppm, there is no problem. There is a remarkable effect that the virus in the pharynx can be removed without giving pleasure and with a short period of rinsing for several seconds to several tens of seconds.
  • the effective chlorine concentration is 50 ppm or more and the pH ratio is high in the ratio of hypochlorous acid (HClO), bacteria that are prokaryotes having no nuclear membrane
  • the effective chlorine concentration is 300 ppm or less, preferably 250 ppm or less, more preferably 200 ppm or less. The protective action of the cell nucleus by the nuclear membrane is not impaired, and thus the damage to the epithelial cells of the human body can be minimized.
  • the effective chlorine concentration is 50 to 300 ppm, preferably 50 to 250 ppm, more preferably 50 to 200 ppm, so that the epithelial cells of the pharynx are not damaged, Only viruses that have entered bacteria and cells can be selectively attacked and killed.
  • hypochlorous acid binds to an amino group present in the capsid, so that the virus can be easily destroyed.
  • the dissolved gas in the secondary product water 60 is removed using the degassing module 11, but there is a concern that a foaming phenomenon may occur because the concentration of the dissolved gas in the secondary product water 60 is low. If not, the step of removing the dissolved gas may be omitted. In such a case, the secondary product water 60 becomes a gargle.
  • FIG. 2 is a diagram showing a generating device 51a used when the dissolved gas removal step is omitted, and the degassing module 11, the vacuum pump 12, and the tertiary generated water tank 14 are omitted from the generating device 21.
  • the stock solution 52 and the dilution water 57 corresponding to one batch of the gargle are weighed and stored in the stock solution tank 3 and the dilution water tank 8 in advance. If the stock solution 52 in an amount larger than one batch of the gargle, for example, an amount corresponding to several batches is stored in the stock solution tank 3 in advance, the amount of the stock solution 52 corresponding to one batch of the gargle is determined. What is necessary is just to provide the water level measurement means for measuring each time. Such water level measuring means can be appropriately configured by, for example, an ultrasonic sensor, an electrode type sensor or the like.
  • the stock solution is electrolyzed and then diluted to produce a gargle, but instead, the stock solution is diluted and then the diluted water is electrolyzed.
  • a gargle may be obtained.
  • the stock solution is electrolyzed and then diluted to produce a gargle (post-dilution).
  • the stock solution is diluted, and then the diluted water is added.
  • the gargle may be obtained by electrolysis (pre-dilution).
  • the dilution water tank 8 is omitted, and instead, a diluted stock solution tank for storing the diluted stock solution is separately provided between the stock solution tank 3 and the electrolytic cell 5. That's fine.
  • the diluted stock solution was electrolyzed in an electrolytic cell to obtain a gargle.
  • the electrolytic cell used was an electrolytic neutral water generating device manufactured by Sakai Engineering Co., Ltd. and sold under the trade name “Perfect Perio” by Noguchi Dental Institute.
  • Test solution A By adding 5% (w / v) of dry ice to distilled water at atmospheric pressure and at room temperature, carbon dioxide constituting the dry ice is dissolved in the distilled water (saturated carbonated water). 0.6% (w / v) was dissolved.
  • Test solution B Saturated carbonated water, which is an intermediate product of test solution A, was diluted 5-fold with distilled water, and then 0.6% (w / v) of sodium chloride was dissolved.
  • Test solution C Saturated carbonated water, which is an intermediate product of the test solution A, was diluted 10 times with distilled water, and then 0.6% (w / v) of sodium chloride was dissolved.
  • Test solution D By exposing distilled water to the atmosphere under atmospheric pressure and room temperature, carbon dioxide in the air was dissolved in the distilled water, and then 0.6% (w / v) of sodium chloride was dissolved.
  • Test method 4 L of the above stock solution was put into a non-membrane type electrolytic cell, and electrolysis was performed with a direct current of 2.8 A.
  • Test Solution A to Test Solution C using saturated carbonated water have a pH range in which hypochlorous acid and sodium bicarbonate can be present in sufficient concentrations, that is, 6 to 8.
  • the pH of the test solution D in which carbon dioxide in the air was naturally dissolved was 9.2. Therefore, it seems that it is difficult to produce both hypochlorous acid and sodium hydrogen carbonate at a sufficient concentration by the method of spontaneously dissolving carbon dioxide in the air.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La préparation pour gargarisme ci-décrite peut éliminer les virus qui sont présents dans le pharynx, sans endommager les cellules muqueuses du pharynx. Plus spécifiquement, la préparation pour gargarisme (63) ci-décrite comprend de l'acide hypochloreux (HClO) et un hydrogénocarbonate de sodium (NaHCO3), contient une concentration de chlore efficace de 50 à 300 ppm, avantageusement, de 50 à 250 ppm, plus avantageusement encore, de 50 à 200 ppm, et a une valeur de pH de 6,3 à 8 inclus, avantageusement, de 7 à 8 inclus. La valeur de pH de la préparation pour gargarisme (63) peut être maintenue dans l'ensemble dans une plage de 6,3 à 8 dans laquelle l'acide hypochloreux (HClO) peut être présent à une concentration élevée, par l'action de l'hydrogénocarbonate de sodium (NaHCO3). Par conséquent, quand la préparation pour gargarisme (63) est introduite dans la cavité buccale et que la gorge est gargarisée avec la préparation pour gargarisme (63) pendant quelques secondes à plusieurs dizaines de secondes, les virus présents dans le pharynx peuvent être rapidement éliminés par l'action germicide de l'acide hypochloreux (HClO) contenu dans la préparation pour gargarisme (63) et l'innocuité de la préparation pour gargarisme pour le corps humain peut être garantie par l'action de tamponnage exercée par l'hydrogénocarbonate de sodium (NaHCO3).
PCT/JP2010/006682 2009-11-16 2010-11-13 Préparation pour gargarisme, procédé et appareil pour sa production WO2011058764A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-260554 2009-11-16
JP2009260554A JP2013028539A (ja) 2009-11-16 2009-11-16 含嗽剤及びその生成方法並びにその生成装置

Publications (1)

Publication Number Publication Date
WO2011058764A1 true WO2011058764A1 (fr) 2011-05-19

Family

ID=43991430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/006682 WO2011058764A1 (fr) 2009-11-16 2010-11-13 Préparation pour gargarisme, procédé et appareil pour sa production

Country Status (2)

Country Link
JP (1) JP2013028539A (fr)
WO (1) WO2011058764A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871278B2 (en) 2011-03-18 2014-10-28 Puricore, Inc. Stabilized hypohalous acid solutions
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
US10601794B2 (en) 2016-08-01 2020-03-24 Google Llc Providing online media content via a satellite broadcast system
WO2021203101A1 (fr) * 2020-04-03 2021-10-07 Phase One Health, Llc Solutions d'acide hypochloreux et leurs procédés d'utilisation
WO2022038507A1 (fr) * 2020-08-17 2022-02-24 Jacobus Johannes Viljoen Solution destinée à être utilisée dans le traitement de l'hypoxémie et d'une asphyxie potentielle
GB2599795A (en) * 2020-09-15 2022-04-13 Facerestoration Ltd Lavage techniques and virucidal compositions comprising hypochlorous solutions
US11452778B2 (en) 2011-03-18 2022-09-27 Urgo Us, Inc. Stabilized hypohalous acid solutions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108025022A (zh) * 2015-09-16 2018-05-11 菲吉拉药业株式会社 次氯酸水溶液

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072697A1 (fr) * 2005-12-20 2007-06-28 Noguchi Dental Medical Research Institute Eau bactericide et procede et appareil pour la produire
JP2008518004A (ja) * 2004-11-01 2008-05-29 スリー、エム、イノベイティブ、プロパティーズ、カンパニー 院内感染を減らす方法
WO2009098873A1 (fr) * 2008-02-08 2009-08-13 Noguchi Dental Medical Research Institute Eau stérilisée, et procédé et dispositif de production de l'eau
WO2009098870A1 (fr) * 2008-02-08 2009-08-13 Noguchi Dental Medical Research Institute Eau de stérilisation dentaire, procédé de production de l'eau, et dispositif de production de l'eau
JP2009242346A (ja) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd 含嗽用組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008518004A (ja) * 2004-11-01 2008-05-29 スリー、エム、イノベイティブ、プロパティーズ、カンパニー 院内感染を減らす方法
WO2007072697A1 (fr) * 2005-12-20 2007-06-28 Noguchi Dental Medical Research Institute Eau bactericide et procede et appareil pour la produire
WO2009098873A1 (fr) * 2008-02-08 2009-08-13 Noguchi Dental Medical Research Institute Eau stérilisée, et procédé et dispositif de production de l'eau
WO2009098870A1 (fr) * 2008-02-08 2009-08-13 Noguchi Dental Medical Research Institute Eau de stérilisation dentaire, procédé de production de l'eau, et dispositif de production de l'eau
JP2009242346A (ja) * 2008-03-31 2009-10-22 Kobayashi Pharmaceut Co Ltd 含嗽用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"perfect perio chiryo", HIGASHI DENTAL CLINIC WEBSITE, 12 September 2009 (2009-09-12), Retrieved from the Internet <URL:http://www.higashi-dental.jp/info22.html> *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576152B2 (en) 2011-03-18 2020-03-03 Urgo Us, Inc. Stabilized hypohalous acid solutions
US9381214B2 (en) 2011-03-18 2016-07-05 Puricore, Inc. Methods for treating skin irritation
US9392787B2 (en) 2011-03-18 2016-07-19 Puricore, Inc. Stabilized hypohalous acid solutions
US9414584B2 (en) 2011-03-18 2016-08-16 Puricore, Inc. Stabilized hypohalous acid solutions
US9925217B2 (en) 2011-03-18 2018-03-27 Realm Therapeutics, Inc. Methods for treating inflammation associated with allergic reaction
US10034942B2 (en) 2011-03-18 2018-07-31 Realm Therapeutics, Inc. Stabilized hypohalous acid solutions
US8871278B2 (en) 2011-03-18 2014-10-28 Puricore, Inc. Stabilized hypohalous acid solutions
US10702549B2 (en) 2011-03-18 2020-07-07 Urgo Us, Inc. Methods for treating skin irritation
US11452778B2 (en) 2011-03-18 2022-09-27 Urgo Us, Inc. Stabilized hypohalous acid solutions
US10601794B2 (en) 2016-08-01 2020-03-24 Google Llc Providing online media content via a satellite broadcast system
WO2021203101A1 (fr) * 2020-04-03 2021-10-07 Phase One Health, Llc Solutions d'acide hypochloreux et leurs procédés d'utilisation
WO2022038507A1 (fr) * 2020-08-17 2022-02-24 Jacobus Johannes Viljoen Solution destinée à être utilisée dans le traitement de l'hypoxémie et d'une asphyxie potentielle
GB2599795A (en) * 2020-09-15 2022-04-13 Facerestoration Ltd Lavage techniques and virucidal compositions comprising hypochlorous solutions

Also Published As

Publication number Publication date
JP2013028539A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2011058764A1 (fr) Préparation pour gargarisme, procédé et appareil pour sa production
JP4369530B2 (ja) 歯科用殺菌水及びその生成方法並びにその生成装置
KR100970708B1 (ko) 미산성 차아염소산수의 제조방법 및 미산성 차아염소수산수의 제조장치
CN101049107A (zh) 消毒粉及其制备方法
WO2000051434A1 (fr) Desinfectant faiblement acide
WO2007072697A1 (fr) Eau bactericide et procede et appareil pour la produire
WO2010004699A1 (fr) Agent d&#39;élimination la mauvaise haleine et son procédé de production
CN106342884A (zh) 一种生活饮用水消毒粉
US20110135562A1 (en) Two stage process for electrochemically generating hypochlorous acid through closed loop, continuous batch processing of brine
JP2013039553A (ja) 長寿命の弱酸性次亜塩素酸水溶液とその製造方法
JP2011229405A5 (fr)
JP2009136814A (ja) 微酸性電解水の調製法
WO2009098873A1 (fr) Eau stérilisée, et procédé et dispositif de production de l&#39;eau
JP2009179582A (ja) 殺菌補助剤及び電解水組成物
JP5893939B2 (ja) オゾン水生成装置及びオゾン水生成方法
JPWO2018003087A1 (ja) 塩素系殺菌剤と微細気泡を組み合わせた殺菌剤、及び殺菌方法
Mehendale et al. HOCl vs OCl−: clarification on chlorine-based disinfectants used within clinical settings
JP2001321771A (ja) 副生ガス処理機能を有する電解水生成装置
CN104973666B (zh) 智能化污水无氯消毒杀菌系统
CN113180056B (zh) 次氯酸消毒液
US11957711B2 (en) Fogonazo solution
KR20090060087A (ko) 오존과 산성도 증가에 의한 바닷물속의 미생물 제거
JP5010037B2 (ja) 電解水の生成方法および組成物
JP3085826U (ja) 逆浸透或いはイオン除去のオゾン水機
CN115226713A (zh) 一种次氯酸消毒剂及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10829724

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10829724

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP